



FOR IMMEDIATE RELEASE

Infraredx Appoints Michael Guarasci as Chief Financial Officer

BURLINGTON, Mass. – December 20, 2012 – Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced the appointment of Michael Guarasci as chief financial officer. Mr. Guarasci joins Infraredx with more than 25 years of experience in financial operations and investment management, and will be responsible for the overall financial strategy and operations for the company. He will report to Donald Southard, president and chief executive officer.

“We are very pleased to welcome Mike to Infraredx as a member of the executive leadership team,” said Mr. Southard. “Mike’s knowledge of the capital markets, in-depth management and financial expertise will be a tremendous asset to the company. We look forward to working closely with him as we continue to execute our corporate business strategy and lay the foundation for our next phase of growth.”

Mr. Guarasci is a seasoned financial executive with extensive experience in strategic planning, operations, investment management and information technology. He joins Infraredx from Indus Capital Partners LLC, where he was chief operating officer, responsible for leading the company’s day-to-day financial operations and overseeing the firm’s senior management committee. Prior to Indus, Mr. Guarasci held leadership positions at the Credit Suisse U.S. Asset Management division, serving as a managing director and chief financial officer. In this role, he helped lead the \$100 billion investment management firm through the integration of Warburg Pincus Asset Management, Garantia Asset Management in Brazil and a handful of additional small acquisitions throughout his six-year tenure at the firm. Mr. Guarasci holds a Bachelor of Science from the Rochester Institute of Technology and a Masters in Business Administration from the State University of New York at Buffalo.

“I am eager to help Infraredx continue to optimize its business strategy and pursue opportunities related to the TVC Imaging System™,” said Mr. Guarasci. “There is a growing need for intravascular imaging technologies that improve the management and treatment of patients with coronary artery disease. This is a very exciting time for the company as it continues to experience accelerated demand for the TVC Imaging System, driven by the increased recognition of the need to accurately characterize vessels to better detect lipid core plaques that are prone to cause stenting-related complications.”

About Infraredx, Inc.

Infraredx, Inc. is a privately-funded medical device company dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease. The company is committed to improving the safety and efficacy of coronary stenting and ultimately serving as part of a strategy to prevent initial coronary events. Through its TVC Imaging System™, Infraredx is changing the way coronary artery disease is diagnosed and treated. The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback. Through the use of both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) technologies, the system helps interventional cardiologists identify which patients are prone to stenting complications by assessing not only the degree of stenosis, but also the presence of lipid core plaque. Founded in 1998, Infraredx is headquartered in Burlington, Mass. For more information, visit www.infraredx.com.



Contacts:

Grant Frazier
Vice President of Marketing
Infraredx, Inc.
781-345-9632
gfrazier@infraredx.com

Susan Heins (media)
Pure Communications, Inc.
864-286-9597
sjheins@purecommunicationsinc.com

###